Evidence map›Paper›PMID 33362794›Full record

ArticleFrontiers in immunology2020

Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells.

Mingya Yang, Lei Wang, Ming Ni, Brigitte Neuber, Sanmei Wang, Wenjie Gong, Tim Sauer, Leopold Sellner, Maria-Luisa Schubert, Angela Hückelhoven-Krauss and 8 more

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 44 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 2 countries.

Mingya YangDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Lei WangDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Ming NiDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Brigitte NeuberDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Sanmei WangDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Wenjie GongDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Tim SauerDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Leopold SellnerDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Maria-Luisa SchubertDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Angela Hückelhoven-KraussDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Jian HongDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui, China.
Lixin ZhuDepartment of General Surgery and Central Laboratory, The First Affiliated Hospital of Anhui Medical University, Anhui, China.
Christian KleistDepartment of Nuclear Medicine, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Volker EcksteinDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Carsten Müller-TidowDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Peter DregerDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Michael SchmittDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Anita SchmittDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
Heidelberg University · DEUniversity Hospital Heidelberg · DEDeutschen Konsortium für Translationale Krebsforschung · DEAnhui Medical University · CNFirst Affiliated Hospital of Anhui Medical University · CNGuiyang Medical University · CNJiangsu Province Hospital · CNNational Center for Tumor Diseases · DESoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cell therapy has shown promising responses in patients with refractory or relapsed aggressive B-cell malignancies that are resistant to conventional chemotherapy or stem cell transplantation. A potentially combinatorial therapeutic strategy may be the inhibition of anti-apoptotic Bcl-2 family proteins, overexpressed in most cancer cells. In this study we investigated the combination of 3rd-generation CD19.CAR-T cells and the BH3 mimetics venetoclax, a Bcl-2 inhibitor, or S63845, a Mcl-1 inhibitor, under three different treatment conditions: pre-sensitization of cancer cells with BH3 mimetics followed by CAR-T cell treatment, simultaneous combination therapy, and the administration of BH3 mimetics after CAR-T cell treatment. Our results showed that administration of CAR-T cells and BH3 mimetics had a significant effect on the quantity and quality of CD19.CAR-T cells. The administration of BH3 mimetics prior to CAR-T cell therapy exerted an enhanced cytotoxic efficacy by upregulating the CD19 expression and pro-apoptotic proteins in highly sensitive tumor cells, and thereby improving both CD19.CAR-T cell cytotoxicity and persistence. In simultaneous and post-treatment approaches, however, the quantity of CAR-T cells was adversely affected. Our findings indicate pre-sensitization of highly sensitive tumor cells with BH3 mimetics could enhance the cytotoxic efficacy of CAR-T cell treatment.

Indexed as

Immunotherapy, AdoptiveAntineoplastic AgentsApoptosisApoptosis Regulatory ProteinsB-LymphocytesBridged Bicyclo Compounds, HeterocyclicCell SurvivalCoculture TechniquesCombined Modality TherapyGene Expression Regulation, LeukemicHumansK562 CellsLeukemiaLymphomaReceptors, Chimeric AntigenSulfonamidesAntineoplastic AgentsApoptosis Regulatory ProteinsBridged Bicyclo Compounds, HeterocyclicReceptors, Chimeric AntigenSulfonamidesvenetoclaxapoptosisBH3 mimeticsCD19.CAR-T cellsS63845venetoclax (ABT-199)

Identifiers

PMID33362794
PMCPMC7756123
OpenAlexW3111820228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.